Claims for Patent: 10,328,158

Summary for Patent: 10,328,158

Title:	Compounds and compositions for immunotherapy
Abstract:	The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.
Inventor(s):	Li; Lixin (Beijing, CN)
Assignee:	BIRDIE BIOPHARMACEUTICALS, INC. (Grand Cayman, KY)
Application Number:	15/793,820
Patent Claims:	1. A compound having the structure of Formula (Ib): TM-L-AM (Ib), wherein TM is a targeting moiety that comprises an immunoglobulin that specifically binds to a tumor antigen on a tumor cell, wherein the tumor antigen is selected from the group consisting of CD2, CD19, CD20, CD22, CD37, CD38, CD44, CD47, CD52, CD56, CD79, 5T4, AGS-5, AGS-16, Angiopoietin 2, BT-062, BTLA, CAIX, Carcinoembryonic antigen, CTLA4, Cripto, ErbB1, ErbB2, ErbB3, ErbB4, EGFL7, EGFR, EpCAM, EphA2, EphA3, EphB2, FAP, Folate Receptor, Ganglioside GM3, GD2, gp100, gpA33, GPNMB, Her2, ICOS, IGF1R, KIR, LAG-3, Lewis Y, Mesothelin, c-MET, MN Carbonic anhydrase IX, MUC1, MUC16, Nectin-4, NOTCH, OX40, OX40L, PD-1, PD-L1, PSCA, PSMA, RANKL, ROR1, ROR2, SLC44A4, Syndecan-1, TACI, TAG-72, Tenascin, and TIM3; L is a linker, -T.sub.a-W.sub.w-Y.sub.y-, wherein TM-T.sub.a is ##STR00065## wherein T forms a bond with a sulfur atom of the immunoglobulin, or T is linked to the immunoglobulin via a disulfide bond; a is 0 or 1; R.sup.1 is --C.sub.1-C.sub.10 alkylene-, --C.sub.3-C.sub.8 carbocyclo-, --O--(C.sub.1-C.sub.8 alkyl)-, -arylene-, --C.sub.1-C.sub.10 alkylene-arylene-, -arylene-C.sub.1-C.sub.10 alkylene-, --C.sub.1-C.sub.10 alkylene-(C.sub.3-C.sub.8 carbocyclo)-, --(C.sub.3-C.sub.8 carbocyclo)-C.sub.1-C.sub.10 alkylene-, --C.sub.3-C.sub.8 heterocyclo-, --C.sub.1-C.sub.10 alkylene-(C.sub.3-C.sub.8 heterocyclo)-, --(C.sub.3-C.sub.8 heterocyclo)-C.sub.1-C.sub.10 alkylene-, --(CH.sub.2CH.sub.2O).sub.r--, or --(CH.sub.2CH.sub.2O).sub.r--CH.sub.2--; each W is, independently, an amino acid; w is an integer ranging from 2 to 12; Y is 2-aminoimidazol-5-methanol, 4-aminobutyric acid amide, 2-aminophenylpropionic acid amide, a branched bis(hydroxymethyl)styrene (BHMS), -glycine-, -glycine-glycine-, or a p-aminobenzyl alcohol (PAB) group that is linked to -W.sub.w- via the nitrogen atom of the PAB unit, and connected directly to -AM via a carbonate, carbamate, or ether group; y is 0, 1, or 2; and AM is a radical of an activating moiety that is represented by structure of formula (I): ##STR00066## wherein dashed line represents bond or absence of bond, is the point to be connected to the linker; X is S or --NR.sub.1, R.sub.1 is -W.sub.0-W.sub.1-W.sub.2-W.sub.3-W.sub.4, W.sub.0 is a bond, alkyl, alkenyl, alkynyl, alkoxy, or -alkyl-S-alkyl-, W.sub.1 is a bond, --O--, or --NR.sub.2--, wherein R.sub.2 is hydrogen, alkyl or alkenyl, W.sub.2 is a bond, --O--, --C(O)--, --C(S)--, or --S(O).sub.2--, W.sub.3 is a bond, --NR.sub.3--, wherein R.sub.3 is hydrogen, alkyl or alkenyl, W.sub.4 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, aryloxy, heteroaryl, or heterocyclyl, each of which is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, --NH.sub.2, nitro, -alkyl-hydroxyl, -alkyl-aryl, -alkyl-heteroaryl, -alkyl-heterocyclyl, --O--R.sub.4, --O-alkyl-R.sub.4, -alkyl-O--R.sub.4, --C(O)--R.sub.4, -alkyl-C(O)--R.sub.4, -alkyl-C(O)--O--R.sub.4, --C(O)--O--R.sub.4, --S--R.sub.4, --S(O).sub.2--R.sub.4, --NH--S(O).sub.2--R.sub.4, -alkyl-S--R4, -alkyl-S(O).sub.2--R.sub.4, --NHR.sub.4, --NR.sub.4R.sub.4, --NH-alkyl-R.sub.4, halogen, --CN, --NO.sub.2, and --SH, wherein R.sub.4 is independently hydrogen, alkyl, alkenyl, -alkyl-hydroxyl, aryl, heteroaryl, heterocyclyl, or haloalkyl; Z is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, haloalkyl, heteroaryl, heterocyclyl, each of which can be optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, halogen, cyano, nitro, --N(R.sub.5).sub.2, -alkoxy-alkyl, -alkoxy-alkenyl, --C(O)-alkyl, --C(O)--O-alkyl, --O--C(O)-alkyl, --C(O)--N(R.sub.5).sub.2, aryl, heteroaryl, --CO-aryl, and --CO-heteroaryl, wherein each R.sub.5 is independently hydrogen, alkyl, haloalkyl, -alkyl-aryl, or -alkyl-heteroaryl; R is hydrogen, alkyl, alkoxy, haloalkyl, halogen, aryl, heteroaryl, heterocyclyl, each of which is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, --NH.sub.2, nitro, -alkyl-hydroxyl, -alkyl-aryl, -alkyl-heteroaryl, -alkyl-heterocyclyl, --O--R.sub.4, --O-alkyl-R.sub.4, -alkyl-O--R.sub.4, --C(O)--R.sub.4, --C(O)--NH--R.sub.4, --C(O)--NR.sub.4R.sub.4, -alkyl-C(O)--R.sub.4, -alkyl-C(O)--O--R.sub.4, --C(O)--O--R.sub.4, --O--C(O)--R.sub.4 , --S--R.sub.4, --C(O)--S--R.sub.4, --S--C(O)--R.sub.4, --S(O).sub.2--R.sub.4, --NH--S(O).sub.2--R.sub.4, -alkyl-S--R.sub.4, - alkyl-S(O).sub.2--R.sub.4, --NHR.sub.4, --NR.sub.4R.sub.4, --NH-alkyl-R.sub.4, halogen, --CN, and --SH, wherein R.sub.4 is independently hydrogen, alkyl, alkenyl, alkoxy, -alkyl-hydroxyl, aryl, heteroaryl, heterocyclyl, or haloalkyl; n is 0, 1, 2, 3, or 4; Y is --NR.sub.6R.sub.7, --CR.sub.6R.sub.7R.sub.8, or -alkyl-NH.sub.2, each of which can be optionally substituted by one or more substituents selected from the group consisting of hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, --NH.sub.2, halogen, --N(R.sub.5).sub.2, -alkoxy-alkyl, -alkoxy-alkenyl, --C(O)-alkyl, --C(O)--O-alkyl, --C(O)--N(R.sub.5).sub.2, aryl, heteroaryl, --CO-aryl, and --CO-heteroaryl, wherein R.sub.6, R.sub.7 and R.sub.8 are independently hydrogen, alkyl, alkenyl, alkoxy, alkylamino, dialkylamino, alkylthio, arylthio, -alkyl-hydroxyl, -alkyl-C(O)--O--R.sub.9, -alkyl-C(O)--R.sub.9, or -alkyl-O--C(O)--R.sub.9, wherein each R.sub.5 is independently hydrogen, alkyl, haloalkyl, -alkyl-aryl, or -alkyl-heteroaryl, wherein R.sub.9 is hydrogen, alkyl, alkenyl, halogen, or haloalkyl; X and Z taken together may optionally form a (5-9)-membered ring; or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1, wherein W.sub.w is a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, or decapeptide. 3. The compound of claim 1, wherein X is --NR.sub.1, R.sub.1 is alkyl, -alkyl-W.sub.4, -alkyl-O-W.sub.4, -alkyl-NH--C(O)-W.sub.4, -alkoxy-NH--C(O)-W.sub.4, -alkyl-NH--C(O)--NH-W.sub.4, -alkoxy-NH--C(O)--NH-W.sub.4, -alkyl-S(O).sub.2-W.sub.4, or -alkyl-NH--C(S)-W.sub.4. 4. The compound of claim 1, wherein X is S. 5. The compound of claim 1, wherein Z is hydrogen, alkyl, alkoxy, aryl, heteroaryl, haloalkyl, each of which is optionally substituted by one to three substituents selected from the group consisting of hydroxyl, alkyl, aryl, heteroaryl, heterocyclyl, cyano, -alkoxy-alkyl, nitro, and --N(R.sub.5).sub.2, wherein each R.sub.5 is independently hydrogen, alkyl, haloalkyl, -alkyl-aryl, or -alkyl-heteroaryl. 6. The compound of claim 1, wherein n is 1 or 2, R is aryl or heteroaryl each of which is optionally substituted by one to three substituents selected from the group consisting of hydroxyl, alkoxy, -alkyl-hydroxyl, --O--R.sub.4, --O-alkyl-R.sub.4, -alkyl-O--R.sub.4, --C(O)--R.sub.4, --C(O)--NH--R.sub.4, --C(O)--NR.sub.4R.sub.4, -alkyl-C(O)--R.sub.4, -alkyl-C(O)--O--R.sub.4, --C(O)--O--R.sub.4, --O--C(O)--R.sub.4, --S--R.sub.4, --C(O)--S--R.sub.4, --S--C(O)--R.sub.4, --S(O).sub.2--R.sub.4, --NH--S(O).sub.2--R.sub.4, -alkyl-S--R.sub.4, -alkyl-S(O).sub.2--R.sub.4, --NHR.sub.4, --NR.sub.4R.sub.4, --NH-alkyl-R.sub.4, halogen, --CN, and --SH, wherein R.sub.4 is independently hydrogen, alkyl, alkenyl, alkoxy, -alkyl-hydroxyl, aryl, heteroaryl, heterocyclyl, or haloalkyl. 7. The compound of claim 1, wherein Y is --NH.sub.2, -alkyl-NH.sub.2, each of which is optionally substituted by one to three substituents selected from the group consisting of alkyl, alkoxy, alkenyl, and alkynyl. 8. The compound of claim 1, wherein AM is a compound selected from the group consisting of: 2-propylthiazolo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, 4-amino-2-(ethoxymethyl)-a,a-di-methyl-1H-imidazo[4,5-c]quinoline-1-ethan- ol, 1-(4-amino-2-ethylaminomethylimidazo-[4,5-c]quinolin-1-yl)-2-methylpro- pan-2-ol, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl-]meth- anesulfonamide, 4-amino-2-ethoxymethyl-aa-dimethyl-6,7,8,9-tetrahydro-1h-imidazo[4,5-c]qu- inoline-1-ethanol, 4-amino-aa-dimethyl-2-methoxyethyl-1h-imidazo[4,5-c]quinoline-1-ethanol, 1-{2-[3-(benzyloxy)propoxy]ethyl}-2-(ethoxymethyl)-1H-imidazo[4,5-c]quino- lin-4-amine, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)butyl]-n'-b- utylurea, N1-[2-(4-amino-2-butyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)e- thyl]-2-amino-4-methylpentanamide, N-(2-{2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy- }ethyl)-n'-phenylurea, 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-a- mine, 1-{4-[(3,5-dichlorophenyl)sulfonyl]butyl}-2-ethyl-1H-imidazo[4,5-c]q- uinolin-4-amine, N-(2-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}e- thyl)-n'-cyclohexylurea, N-{3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-n'-- (3-cyanophenyl)thiourea, N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-2,2-dimethylpropyl]- benzamide, 2-butyl-1-[3-(methylsulfonyl)propyl]-1H-imidazo[4,5-c]quinolin-- 4-amine, N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,- 1-dimethylethyl}-2-ethoxyacetamide, 1-[4-amino-2-ethoxymethyl-7-(pyridin-4-yl)-1H-imidazo[4,5-c]quinolin-1-yl- ]-2-methylpropan-2-ol, 1-[4-amino-2-(ethoxymethyl)-7-(pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-1-- yl]-2-methylpropan-2-ol, N-{3-[4-amino-1-(2-hydroxy-2-methylpropyl)-2-(methoxyethyl)-1H-imidazo[4,- 5-c]quinolin-7-yl]phenyl}methanesulfonamide, 1-[4-amino-7-(5-hydroxymethylpyridin-3-yl)-2-(2-methoxyethyl)-1H-imidazo[- 4,5-c]quinolin-1-yl]-2-methylpropan-2-ol, 3-[4-amino-2-(ethoxymethyl)-7-(pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-1-- yl]propane-1,2-diol, 1-[2-(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)-1,1-dimethyl- ethyl]-3-propylurea, 1-[2-(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)-1,1-dimethyl- ethyl]-3-cyclopentylurea, 1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-(ethoxymethyl)-7-(4-hydroxym- ethylphenyl)-1H-imidazo[4,5-c]quinolin-4-amine, 4-[4-amino-2-ethoxymethyl-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]q- uinolin-7-yl]-N-methoxy-N-methylbenzamide, 2-ethoxymethyl-N1-isopropyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinoline- -1,4-diamine, 1-[4-amino-2-ethyl-7-(pyridin-4-yl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-met- hylpropan-2-ol, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfona- mide, and N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)bu- tyl]-n'-cyclohexylurea. 9. The compound of claim 1, wherein TM binds to a tumor cell specifically or preferably in comparison to a non-tumor cell. 10. The compound of claim 1, wherein the immunoglobulin comprises an antibody or a functional fragment thereof. 11. The compound of claim 1, wherein the immunoglobulin comprises Rituxan.RTM. (rituximab), Herceptin.RTM. (trastuzumab), Erbitux.RTM. (cetuximab), Vectibix.RTM. (Panitumumab), Arzerra.RTM. (Ofatumumab), Benlysta.RTM. (belimumab), Yervoy.RTM. (ipilimumab), Perjeta.RTM. (Pertuzumab), Tremelimumab, Nivolumab, Dacetuzumab, Urelumab, MPDL3280A, Lambrolizumab, Blinatumomab, a functional fragment thereof; or a mixture thereof. 12. A pharmaceutical composition comprising an effective amount of the compound according to claim 1 and one or more pharmaceutically acceptable carriers. 13. The pharmaceutical composition of claim 12, further comprising an effective amount of an additional therapeutic agent. 14. The pharmaceutical composition of claim 13, wherein the additional therapeutic agent is an anticancer agent selected from an antimetabolite, an inhibitor of topoisomerase I and II, an alkylating agent, a microtubule inhibitor, an antiandrogen agent, a GNRh modulator, and a mixture thereof. 15. The compound of claim 8, wherein the AM is 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. 16. The compound of claim 8, wherein the AM is 4-amino-2-(ethoxymethyl)-a,a-di-methyl-1H-imidazo[4,5-c]quinoline-1-ethan- ol. 17. The compound of claim 8, wherein the AM is 1-(4-amino-2-ethylaminomethylimidazo-[4,5-c]quinolin-1-yl)-2-methylpropan- -2-ol. 18. The compound of claim 1, wherein the tumor antigen is PD-L1. 19. The compound of claim 1, wherein the tumor antigen is CD20. 20. The compound of claim 1, wherein the tumor antigen is Her2. 21. The compound of claim 1, wherein the tumor antigen is EGFR. 22. The compound of claim 1, wherein W.sub.w is ##STR00067## wherein R.sup.2 is hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, --CH.sub.2OH, --CH(OH)CH.sub.3, --CH.sub.2CH.sub.2SCH.sub.3, --CH.sub.2CONH.sub.2, --CH.sub.2COOH, --CH.sub.2CH.sub.2CONH.sub.2, --CH.sub.2CH.sub.2COOH, --(CH.sub.2).sub.3NHC(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.3NH.sub.2, --(CH.sub.2).sub.3NHCOCH.sub.3, --(CH.sub.2).sub.3NHCHO, --(CH.sub.2).sub.4NHC(.dbd.NH)NH.sub.2, --(CH.sub.2).sub.4NH.sub.2, --(CH.sub.2).sub.4NHCOCH.sub.3, --(CH.sub.2).sub.4NHCHO, --(CH.sub.2).sub.3NHCONH.sub.2, --(CH.sub.2).sub.4NHCONH.sub.2, --CH.sub.2CH.sub.2CH(OH)CH.sub.2NH.sub.2, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, phenyl, cyclohexyl, ##STR00068## 23. The compound of claim 1, wherein W.sub.w is ##STR00069## wherein R.sup.3 is benzyl, methyl, isopropyl, isobutyl, sec-butyl, or ##STR00070## and R.sup.4 is (CH.sub.2).sub.4NH.sub.2, (CH.sub.2).sub.3NHCONH.sub.2, methyl, or (CH.sub.2).sub.3NHC(.dbd.NH)NH.sub.2. 24. The compound of claim 1, wherein W.sub.w is ##STR00071## wherein R.sup.3 is benzyl and R.sup.4 is (CH.sub.2).sub.4NH.sub.2, R.sup.3 is methyl and R.sup.4 is (CH.sub.2).sub.4NH.sub.2, R.sup.3 is isopropyl and R.sup.4 is (CH.sub.2).sub.4NH.sub.2, R.sup.3 is isopropyl and R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2, R.sup.3 is benzyl and R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2, R.sup.3 is isobutyl and R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2, R.sup.3 is sec-butyl and R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2, R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2 and R.sup.3 is ##STR00072## R.sup.3 is benzyl and R.sup.4 is methyl, or R.sup.3 is benzyl and R.sup.4 is (CH.sub.2).sub.3NHC(.dbd.NH)NH.sub.2. 25. The compound of claim 1, wherein Y.sub.y is ##STR00073## m is 0; and W.sub.w is ##STR00074## wherein R.sup.3 is benzyl and R.sup.4 is (CH.sub.2).sub.4NH.sub.2, R.sup.3 is methyl and R.sup.4 is (CH.sub.2).sub.4NH.sub.2, R.sup.3 is isopropyl and R.sup.4 is (CH.sub.2).sub.4NH.sub.2, R.sup.3 is isopropyl and R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2, R.sup.3 is benzyl and R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2, R.sup.3 is isobutyl and R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2, R.sup.3 is sec-butyl and R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2, R.sup.4 is (CH.sub.2).sub.3NHCONH.sub.2 and R.sup.3 is ##STR00075## R.sup.3 is benzyl and R.sup.4 is methyl, or R.sup.3 is benzyl and R.sup.4 is (CH.sub.2).sub.3NHC(.dbd.NH)NH.sub.2. 26. The compound of claim 1, wherein TM-T.sub.a is ##STR00076## 27. The compound of claim 1, wherein TM-T.sub.a is ##STR00077## 28. The compound of claim 1, wherein TM-T.sub.a is ##STR00078## 29. The compound of claim 1, wherein Y.sub.y is ##STR00079## Q is --C.sub.1-C.sub.8 alkyl, --C.sub.1-C.sub.8 alkoxy, halogen, nitro, or cyano; m is an integer ranging from 0 to 4. 30. The compound of claim 1, wherein -T.sub.a-W.sub.w-Y.sub.y- is ##STR00080## 31. The compound of claim 1, wherein R.sup.1 is --(CH.sub.2).sub.5--. 32. The compound of claim 1, wherein R.sup.1 is --(CH.sub.2CH.sub.2O).sub.r--CH.sub.2--, and r is 2. 33. The compound of claim 1, wherein AM is a radical of ##STR00081## 34. The compound of claim 1, wherein AM is a radical of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. 35. The compound of claim 8, wherein AM is a radical of 4-amino-2-(ethoxymethyl)-a,a-di-methyl-1H-imidazo[4,5-c]quinoline-1-ethan- ol. 36. The compound of claim 8, wherein AM is a radical of 1-(4-amino-2-ethylaminomethylimidazo-[4,5-c]quinolin-1-yl)-2-methylpropan- -2-ol. 37. The compound of claim 1, wherein AM is a radical of ##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086## ##STR00087## ##STR00088## ##STR00089## 38. The compound of claim 1, wherein the activating moiety is capable of activating a dendritic cell, a macrophage, a monocyte, a myeloid-derived suppressor cell, an NK cell, a B cell, a T cell, a tumor cell, or a combination thereof.

Details for Patent 10,328,158

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,328,158	2037-10-25
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	February 19, 2002	10,328,158	2037-10-25
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	10,328,158	2037-10-25
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	10,328,158	2037-10-25